On Wednesday, Kinder Morgan Inc (NYSE:KMI)’s shares inclined 1.66% to $30.69.
Kinder Morgan, Inc. (KMI) declared it will extend its current binding open season to review shipper comments and interest received to date, in addition to continue to seek commitments for the projected Utica Marcellus Texas Pipeline (UMTP) project, which would transport natural gas liquids and condensate produced from the Utica and Marcellus basins to delivery points along the Texas Gulf Coast, counting connectivity to a Kinder Morgan dock located along the Houston Ship Channel. The binding open season planned to end recently will now end at 5 p.m. Central Time on Dec. 15, 2015.
The projected project would involve the abandonment and conversion of 964 miles of natural gas service on KMI’s existing Tennessee Gas Pipeline, the construction of about 200 miles of new pipeline from Louisiana to Texas, new storage in Ohio and 120 miles of new laterals to provide basin connectivity.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
Gilead Sciences, Inc. (NASDAQ:GILD)’s shares dropped -0.02% to $111.03.
Gilead Sciences, Inc. (GILD) declared the pricing of senior unsecured notes in an aggregate principal amount of $10 billion, in an underwritten, registered public offering, comprising of six tranches:
- $1,000 million of 1.850% senior notes maturing in 2018
- $2,000 million of 2.550% senior notes maturing in 2020
- $1,000 million of 3.250% senior notes maturing in 2022
- $2,750 million of 3.650% senior notes maturing in 2026
- $1,000 million of 4.600% senior notes maturing in 2035
- $2,250 million of 4.750% senior notes maturing in 2046
Gilead intends to use the net proceeds from the offering for general corporate purposes, which may comprise the repayment of debt, working capital, payment of dividends and the repurchase of its outstanding common stock following its authorized share repurchase program.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
At the end of Wednesday’s trade, Energy Transfer Equity LP (NYSE:ETE)‘s shares surged 1.62% to $25.72.
After a nine-month battle that became public this summer, Energy Transfer Equity LP is close to winning its takeover fight for rival pipeline operator Williams Cos., people with knowledge of the matter said, according to the Bloomberg.
The companies are in advanced talks about a deal that could be declared in the next week and a half, said the people, who asked not to be identified because the matter is private. The transaction hasn’t been finalized and talks could still fall through, the people said.
Bloomberg divulged A deal between Energy Transfer and Williams would create the world’s largest operator of infrastructure for moving and processing oil and gas. It would also end a battle that intensified in June when Williams rejected Energy Transfer’s unsolicited bid and hired banks to explore a sale.
Energy Transfer offered to buy Williams for $64 a share in stock, or about $48 billion. Counting debt, the deal would have been valued at about $53 billion, according to declarement at the time. It’s not clear if Energy Transfer has changed the terms of its initial proposal.
Energy Transfer Equity, L.P., through its auxiliaries, provides diversified energy-related services in the Unites States. It owns and operates about 7,700 miles of natural gas transportation pipelines and 3 natural gas storage facilities located in the state of Texas; and about 12,800 miles of interstate natural gas pipeline. Bloomberg reported.
Novavax, Inc. (NASDAQ:NVAX), ended its Wednesday’s trading session with -2.16% loss, and closed at $9.95.
Novavax, Inc., (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.
Direct immunization of infants is complicated by their immature immune systems which are unable to fight off viral infection early in life when infants are most vulnerable to RSV. In mammals, the passage of maternal antibodies to offspring is largely achieved either by in utero transplacental transfer of immunoglobulin G antibodies (IgG) or by postpartum breast-feeding of colostral milk containing high levels of IgG and sIgA.2 For human infants, maternally-derived IgG appears to be offered entirely in utero, via transplacental Fc receptor-mediated antibody transfer.2 The protective effects of human serum IgG, transferred from mothers to infants in utero,2 against a number of infections, counting influenza and pertussis, has been well-described.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
